

# A Supportive Partner in the Face of Evolving Guidance

## THE CHALLENGE

In 2022, NICE introduced an expedited appraisal process based on cost-comparison analysis (CCA) for therapies with equivalent efficacy and safety profiles to another recommended treatment. Soon after this update to NICE's processes, Stratenym's client sought a reimbursement recommendation using a CCA as a pilot under the Proportionate Approach to Technology Appraisals (PATT).

## THE SUCCESSFUL OUTCOME

Despite the novelty of the process, the product was recommended for reimbursement by NICE in record time.

## THE STRATENYM SOLUTION

Any pilot is a true test of the ability of the team—internal and external stakeholders and vendors alike—to pull together and work cohesively toward the same goal. Stratenym worked closely with our client and all of their other supporting vendors to develop a compelling and precise CCA Company Evidence Submission—on time and within budget. Stratenym experts not only meticulously combed through the guidance documents to make sure the submission adhered to guidelines, but we also drafted the content for the entire submission, executed the systematic literature review (SLR) that supported the submission, and assisted our client in responding to External Assessment Group (EAG) queries.



*“Thank you for everything you’ve done this year, and for generally being a wonderful partner.”*

## GET IN TOUCH

**Mark Roberts, PhD**  
VP Medical Communications  
E: [mark.roberts@stratenym.com](mailto:mark.roberts@stratenym.com)  
W: [www.stratenym.com](http://www.stratenym.com)

